 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Repligen Corporation (RGEN) develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide.
It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand.
In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations.
Shares have formed a bullish "flag" following the company's recent quarterly report. On May 8th, Repligen Cp (RGEN) reported 1st Quarter March 2019 earnings of $0.28 per share on revenue of $60.6 million. The consensus earnings estimate was $0.26 per share on revenue of $60.5 million. Revenue grew 35.3% on a year-over-year basis.
The company said it expects 2019 earnings of $0.84 to $0.90 per share on revenue of $235.0 million to $241.0 million. The company's previous guidance was earnings of $0.81 to $0.86 per share on revenue of $218.0 million to $225.0 million and the current consensus earnings estimate is $0.83 per share on revenue of $220.4 million for the year ending December 31, 2019.. Higher share prices are expected for this stock.
Entry Point: $70.00
Stop Loss: $67.50
Trading Range: $42.80 to $71.21
Target Price: $77.00
RGEN closed at $77.80
